Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ365MR)

This product GTTS-WQ365MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ365MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14968MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ6528MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ11571MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ6989MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ3551MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ14137MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ14216MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ13590MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA QAX-576
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW